Abstract:Senescence refers to a cellular state marked by irreversible cell cycle arrest and the secretion of pro-inflammatory and tissue-remodeling factors. The senescence associated secretory phenotype (SASP) impacts the tissue microenvironment and provides cues for the immune system to eliminate senescent cells (SCs). Cellular senescence has a dual nature; it can be beneficial during embryonic development, tissue repair, and tumor suppression, but it can also be detrimental in the context of chronic stress, persistent tissue injury, together with an impairment in SC clearance. Recently, the accumulation of SCs has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH), a progressive condition affecting the pre-capillary pulmonary arterial bed. PAH is characterized by endothelial cell (EC) injury, inflammation, and proliferative arterial remodeling, which leads to right heart failure and premature mortality. While vasodilator therapies can improve symptoms, there are currently no approved treatments capable of reversing the obliterative arterial remodeling. Ongoing endothelial injury and dysfunction is central to the development of PAH, perpetuated by hemodynamic perturbation leading to pathological intimal shear stress. The precise role of senescent ECs in PAH remains unclear. Cellular senescence may facilitate endothelial repair, particularly in the early stages of disease. However, in more advanced disease the accumulation of senescent ECs may promote vascular inflammation and occlusive arterial remodeling. In this review, we will examine the evidence that supports a role of endothelial cell senescence to the pathogenesis of PAH. Furthermore, we will compare and discuss the apparent contradictory outcomes with the use of interventions targeting cellular senescence in the context of experimental models of pulmonary hypertension. Finally, we will attempt to propose a framework for the understanding of the complex interplay between EC injury, senescence, inflammation and arterial remodeling, which can guide further research in this area and the development of effective therapeutic strategies.

Potential Role of Cellular Senescence in Pulmonary Arterial Hypertension

Epigenetic Regulation of Pulmonary Arterial Hypertension

Cellular senescence in the pathogenesis of pulmonary arterial hypertension: the good, the bad and the uncertain

Regulatory role of autophagy in development of pulmonary artery hypertension

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Cell Death in Pulmonary Arterial Hypertension

Pulmonary Artery Smooth Muscle Cell Senescence Promotes the Proliferation of PASMCs by Paracrine IL-6 in Hypoxia-Induced Pulmonary Hypertension

Stem/Progenitor Cells and Pulmonary Arterial Hypertension.

Stem/Progenitor Cells And Pulmonary Arterial Hypertension

Endothelial senescence mediates hypoxia-induced vascular remodeling by modulating PDGFB expression

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Endothelial cells in the pathogenesis of pulmonary arterial hypertension

Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Potential Role of Cellular Senescence in Asthma

Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension

Bmi-1 alleviates adventitial fibroblast senescence by eliminating ROS in pulmonary hypertension

Cellular senescence impairs the reversibility of pulmonary arterial hypertension

General Capillary Endothelial Cells Undergo Reprogramming into Arterial Endothelial Cells in Pulmonary Hypertension through HIF-2α/Notch4 Pathway

Emerging connectivity of programmed cell death pathways and pulmonary vascular remodelling during pulmonary hypertension